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Abstract
Background: Nineteen patients with deletions in chromosome 6p22-p24 have been published so far. The
syndromic phenotype is varied, and includes intellectual disability, behavioural abnormalities, dysmorphic features
and structural organ defects. Heterogeneous deletion breakpoints and sizes (1–17 Mb) and overlapping phenotypes
have made the identification of the disease causing genes challenging. We suggest JARID2 and ATXN1, both
harbored in 6p22.3, as disease causing genes.
Methods and results: We describe five unrelated patients with de novo deletions (0.1-4.8 Mb in size) in
chromosome 6p22.3-p24.1 detected by aCGH in a cohort of approximately 3600 patients ascertained for
neurodevelopmental disorders. Two patients (Patients 4 and 5) carried non-overlapping deletions that were
encompassed by the deletions of the remaining three patients (Patients 1–3), indicating the existence of two
distinct dosage sensitive genes responsible for impaired cognitive function in 6p22.3 deletion-patients. The smallest
region of overlap (SRO I) in Patients 1–4 (189 kb) included the genes JARID2 and DTNBP1, while SRO II in Patients
1–3 and 5 (116 kb) contained GMPR and ATXN1. Patients with deletion of SRO I manifested variable degrees of
cognitive impairment, gait disturbance and distinct, similar facial dysmorphic features (prominent supraorbital
ridges, deep set eyes, dark infraorbital circles and midface hypoplasia) that might be ascribed to the
haploinsufficiency of JARID2. Patients with deletion of SRO II showed intellectual disability and behavioural
abnormalities, likely to be caused by the deletion of ATXN1. Patients 1–3 presented with lower cognitive function
than Patients 4 and 5, possibly due to the concomitant haploinsufficiency of both ATXN1 and JARID2. The
chromatin modifier genes ATXN1 and JARID2 are likely candidates contributing to the clinical phenotype in
6p22-p24 deletion-patients. Both genes exert their effect on the Notch signalling pathway, which plays an
important role in several developmental processes.
Conclusions: Patients carrying JARID2 deletion manifested with cognitive impairment, gait disturbance and a
characteristic facial appearance, whereas patients with deletion of ATXN1 seemed to be characterized by intellectual
disability and behavioural abnormalities. Due to the characteristic facial appearance, JARID2 haploinsufficiency might
represent a clinically recognizable neurodevelopmental syndrome.
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Background
Deletions involving chromosome 6p22-p24 have previously
been reported in 19 patients (18 patients reviewed by
Celestino-Soper [1] and one described in [2]). In addition,
an electively aborted 27 week-old fetus with a de novo
deletion in 6p22.3-p24.3 was described with multiple
malformations [3]. Most reported subjects were develop-
mentally delayed and presented with a heterogeneous
pattern of dysmorphic facial features, including various eye
abnormalities, and congenital anomalies, including cranio-
facial malformations, kidney- and heart defects. Different
breakpoints and sizes (1 to 17 Mb) of the deletions might
account for a large part of this variability. However, based
on the deletion overlap in their patient and six out of seven
previously reported subjects, Bremer et al. proposed that
the critical gene(s) were located in 6p22.3 [4].
We describe five unrelated patients with variable
degree of cognitive impairment ranging from borderline
IQ to severe intellectual disability, and de novo deletions
(0.1-4.8 Mb) within 6p22.3-p24.1 detected by aCGH
analysis. Two non-overlapping deletions in Patients 4 and
5 defined the two smallest regions of overlap (SRO I and II,
189 and 116 kb, respectively) in our patients, each deleted
in four of the five patients. Both regions were located in
6p22.3 and contained only two genes each, thereby
facilitating the identification of the disease causing
genes in this region.
Based on their function as chromatin modifier genes that
play a role in the Notch signaling pathway, we suggest that
JARID2 and ATXN1 are likely to be the critical genes for
cognitive function within SRO I and II, respectively. In
addition, JARID2 haploinsufficiency is likely to be the main
contributor to the neurodevelopmental syndrome in
Patients 1–4 consisting of impaired cognitive function, gait
disturbance and distinct, similar dysmorphic facial features
characterized by prominent supraorbital ridges, deep set
eyes, dark infraorbital circles and midface hypoplasia.
Methods
Cytogenetic analysis
Chromosome metaphase spreads from peripheral blood
of the five patients were analysed by standard G-banding
methods.
Array-comparative genome hybridization (aCGH)
DNA from leucocytes from the five patients and their
parents was analysed by aCGH using one of the com-
mercially available Human Genome CGH Microarrays
4x44K, 2x105A, 4x180K or 244A (Agilent Technologies
Inc., Santa Clara, CA) according to the manufacturer’s
recommendations. Samples were sex-matched with
Human Genomic DNA (Promega, Madison, WI). Data
were processed with Feature Extraction and DNA Analytics
v4.0.76 (Agilent Technologies Inc.). All genomic positions
were based on the February 2009 human reference
sequence (GRCh37/hg19) by the Genome Reference
Consortium.
Real-time PCR
Quantitative real time-PCR (qPCR) amplifications were
carried out on genomic DNA. Reverse transcriptase real
time-PCR (RT-PCR) was performed on RNA from
peripheral blood, after conversion of RNA to cDNA
(High Capacity cDNA Reverse Transcription Kit, Life
Technologies Corporation, Carlsbad, CA). SYBR Green
JumpStart Taq ReadyMix (Sigma-Aldrich, Saint Louis,
MO) chemistry was used for both qPCR and RT-PCR.
Reactions were run in triplicate on the Applied Biosystems
Real Time PCR 7900 HT Sequence Detector System
according to the manufacturer’s recommendations. qPCR
primers were designed at frodo.wi.mit.edu/primer3 [5], and
the amplification levels were calculated using the 2-ΔΔCt
method [6]. RT-PCR primers targeting JARID2 [GenBank:
NM_004973.3] and ATXN1 [GenBank: NM_001128164.1]
transcripts were designed at ncbi.nlm.nih.gov/tools/
primer-blast (primer sequences supplied in Additional
file 1: Table S1), and the amplification levels were cal-
culated according to Vandesompele et al. [7]. Dissoci-
ation curve analysis revealed a single product for each
primer pair.
Growth standard curves
Norwegian consensus anthropometric measures were
used in this report [8].
Clinical reports
Patient 1 (reported in DECIPHER database with identi-
fication # 256835) was a 15-year-old girl, the second
child to non-consanguineous healthy Norwegian parents.
Pregnancy and delivery were uneventful, with the following
birth measures: weight 4470 g (97th centile), length 55 cm
(>97th centile) and occipitofrontal circumference (OFC)
36 cm (75th centile). Global developmental delay was
present from early childhood and she walked independ-
ently at 3.5 years of age. Testing with Reynell Develop-
mental Language Scales and British Picture Vocabulary
Scale at age 9 years, and Leiter International Perform-
ance Scale-Revised (Leiter-R) at age 9 and 10 years,
indicated a mental age between 3 and 4 years, with ex-
pressive language below 3 years. The test results were
consistent with moderate intellectual disability (IQ 35–49).
A cerebral magnetic resonance imaging (MRI) examin-
ation at age 8 years showed unspecific periventricular
white matter changes. She has had seizure-suspected
syncope episodes from 13 years of age, but an electro-
encephalogram (EEG) was normal. At the last examin-
ation, at age 15 years, her weight was 53.7 kg (50th
centile), height 157.5 cm (10th centile) and OFC 54 cm
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(25th centile). Her vocabulary consisted of 20–30 words,
no sentences, and her articulation was blurred. She was
hyperactive with a short concentration span, and had sleep-
ing difficulties. She demonstrated unsteady and broad-
based gait with difficulties standing on one leg at a time,
and a remarkable inability to jump on one as well as on
two legs (Additional file 2: Video Patient 1). Dyspraxia
was suggested by a discrepancy in performance between
on-command and self-initiated tasks and language.
Muscle tone was normal. Hearing and vision were nor-
mal. Ultrasound scan of kidneys was normal. She had
pes planovalgus, short halluxes and apparently long 2nd
toes bilaterally. X-ray images of hands and feet revealed
shortening of the 1st and 3rd -5th metacarpal bones of
the left hand and the 1st and 5th metacarpal bones of the
right hand, and bilateral short 1st metatarsal bones
(Additional file 3: Figure S1). Dysmorphic facial features
(Figure 1A) and minor congenital anomalies in this pa-
tient are listed in Table 1.
Patient 2 was a 4-year-old boy, the third child to non-
consanguineous healthy Norwegian and English parents.
Pregnancy and delivery were uneventful, with the following
birth measures: weight 4090 g, length 52 cm and OFC 36
cm (all measures at the 75th centile). From an early stage
his eye contact and speech were delayed, and he walked in-
dependently at 2 years of age. Testing with Bayley Scales of
Infant and Toddler Development, third edition (Bayley III)
at age 3.5 years showed cognitive functioning correspon-
ding to 1.5 years, suggesting moderate intellectual disability.
He did not fulfill the criteria for autism spectrum disorders
(ASDs) according to the Autism Diagnostic Observation
Schedule (ADOS). At the same age, a cerebral MRI
examination was normal. Seizure-suspected syncope
episodes occurred during infancy. EEG performed at
age 8 months was normal, whereas cardiologic work-up
revealed an atrial septal defect that closed spontaneously.
At the last examination, at age 4 years, his weight was 19
kg (90th centile), height 105 cm (75th centile) and OFC 52
cm (50th centile). His language development was severely
delayed; he could only speak a few words. He had a broad-
based and unsteady gait (Additional file 4: Video Patient 2)
and seemed unable to stand on one leg at a time. Muscle
tone was normal. Hearing and vision were normal.
Dysmorphic facial features (Figure 1B) and minor conge-
nital anomalies in this patient are listed in Table 1.
Patient 3 was a 6.5-year-old girl, the first of two children
to non-consanguineous healthy Norwegian parents. Preg-
nancy and delivery were uneventful, with the following
birth measures: weight 3470 g, length 49 cm and OFC
34 cm (all measures at the 25th centile). A large umbilical
hernia was noted at birth. She had muscular hypotonia that
persisted for 3 to 4 months. She crawled at 12 months and
walked at 18 months. At 5 years and 10 months testing
with Bailey II, she showed cognitive functions correspon-
ding to 12 to 13 months, suggesting severe intellectual
disability (IQ 20–34). Evaluation with ADOS showed be-
haviour consistent with ASDs. A cerebral MRI examination
at 3 months was normal. In the neonatal period she had
a few episodes of apnea with cyanosis of unknown
cause, but EEG was normal except for unspecified slow
wave activity, and cardiologic work-up was normal. At
the last examination, at age 6.5 years, her weight was
24.7 kg (50th centile), height 127 cm (90th centile) and
OFC 53.5 cm (75-90th centile). Her language development
Figure 1 Facial appearance of Patient 1 at the age of 13 years (A), Patient 2 at the age of 4 years (B), Patient 3 at the age of 6.5 years
(C), and Patient 4 at the age of 5.5 years (D). All patients have distinct, similar dysmorphic facial features, including prominent supraorbital
ridges, deep set eyes, dark infraorbital circles and midface hypoplasia.
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Table 1 Summary of the aCGH results and clinical data of presently reported patients with 6p22.3-p24.1 deletions
Patient 1 2 3 4 5
Gender (M/F) F M F M F
Age at last
follow-up (y)
15 4 6.5 6.5 17
Deletion
Chromosomal band 6p22.3-p24.1 6p22.3-p23 6p22.3-p23 6p22.3 6p22.3
Position (bp, hg19) 13071924-17918584 15081747-18207178 14545576-16846846 15405377-15594945 16215803-16332297
Deleted candidate
genes
JARID2, ATXN1 JARID2, ATXN1 JARID2, ATXN1 JARID2 ATXN1
Size (kb) 4846 3125 2301 189 116
Agilent array 105A 180K 44K 105A 244A
Face
Broad forehead + + + - -
Prominent forehead - + - - -
Frontal bossing + - + - -
Prominent
supraorbital ridges
+ + + + -
Deep set eyes + + + + -
Hypotelorism + - - - -
Hypertelorism - - + - -
Strabismus + - - + -
Infraorbital dark
circles
+ + + + -
Midface hypoplasia + + + + -
Deep set nasal root + + - + -
Bulbous nasal tip + + + + -
Short philtrum + + - + -
Full lips + + + + -
Marked Cupid's bow + + + + -
Accentuated central
depression lower lip
+ + - + -
Prominent or
pointed chin
+ + + + -
Neurology
Intellectual disability Moderate Moderate Severe Borderline Mild
Gait disturbance + + + + -
Dyspraxia + ? ? + -
Muscle tone Nl Nl Nl (neonatal
hypotonia)
Nl (early-onset
hypotonia)
Nl
Seizures + + - - -
Behavioural
abnormalities
Hyperactivity,
sleeping difficulties
Poor eye contact,
repetetive
behaviour
ASDs, hyperactivity,
sleeping difficulties
Nl Psycotic episode,
aggression,
hyperactivity,
repetetive
behaviour
Other
Structual heart
defects
NE Atrial septal defect - NE NE
Umbilical hernia - - + - -
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was severely delayed with a vocabulary of less than 50
words. She could not speak in sentences. She was hyper-
active with an unsteady gait (Additional file 5: Video
Patient 3), had sleeping difficulties and still used diapers.
Muscle tone was normal. Hearing and vision were normal.
Dysmorphic facial features (Figure 1C) and minor con-
genital anomalies in this patient are listed in Table 1.
Patient 4 was a 6.5-year-old boy, the second of four
children to non-consanguineous Lebanese parents. The
mother and maternal uncle had epilepsy. Pregnancy and
delivery were uneventful, with the following birth
measures: weight 3756 g, length 51 cm and OFC 35 cm
(all measures at the 50th centile). He walked at age 16
months. When tested at age 4 years and 3 months with
Reynell Developmental Language Scales, his language
development was delayed by 1.5 years. Testing with
WPPSI-III at age 6.5 years gave a borderline IQ of 74
(borderline intellectual functioning: IQ 70–84). He per-
formed best on verbal tests, despite being bilingual.
Cerebral MRI and EEG examinations at age 6 years were
normal. At the last examination, at age 6.5 years, his weight
was 23.9 kg (50th centile), height 126 cm (75th centile) and
OFC 52 cm (25th centile). He had balance and coordination
problems (Additional file 6: Video Patient 4). Finger oppo-
sition was inadequate and he performed poorly when asked
to stand on one leg at a time, jump, or walk on his toes or
heals. Muscle tone was normal. Hearing and vision were
normal. Due to early-onset muscular hypotonia he had
been extensively examined for the possibility of neuromus-
cular disease, however, with normal results. Testing for
metabolic abnormalities was also normal. Dysmorphic
facial features (Figure 1D) and minor congenital anomalies
in this patient are listed in Table 1.
Patient 5 was a 17-year-old girl, born as the second of
three children to non-consanguineous Norwegian parents.
The mother had Sjogren syndrome. The pregnancy was
complicated by episodes of maternal bleeding. Delivery was
normal, with the following birth measures: weight 3800 g,
length 52 cm (both at the 75th centile) and OFC unknown.
She walked independently at 14 months, and developed the
stereotypic habit of constantly walking around. At 3 years
and 3 months she showed delayed language and motor
development, and hyperactivity. Testing with Bayley-II gave
a Mental Developmental Index of 55, corresponding to a
developmental age of approximately 2 years. Her language
development was particularly delayed, and she lacked
concentration and impulse control. At 8 years WISC-R
gave an IQ of 60. A recent testing with WISC-IV gave an
IQ slightly below 70, and Wechsler Adult Intelligence
Scale-Fourth Edition (WAIS-IV) and other tests were in
accordance with this, indicating mild intellectual disability
(IQ 50–69). She attended a school for children with learn-
ing disabilities. A cerebral MRI examination at 6 years was
normal. She has had episodes of uncontrolled anger out-
bursts, sometimes with violent behaviour, and at age 14
she had a psychotic episode. Over the years she has dis-
played stereotypic behaviour such as chewing on her fin-
gers, but she has not been considered as having ASDs. At
the last examination, at age 17 years, she was obese with a
Body Mass Index (BMI) of 30.6 and height 162.5 cm (25th
centile). She had a mild unsteadiness when standing with
her eyes closed. Muscle tone was normal. Hearing and vi-
sion were normal. Testing for fragile X syndrome and work
up for detection of abnormal metabolites in the urine were
normal. Dysmorphic features were not noted (consent to
publish photos of this patient was not obtained).
Results
Karyotype analysis of all five patients was normal. Deletions
in chromosome 6p22.3-p24.1 of 116 kb to 4.8 Mb in size
Table 1 Summary of the aCGH results and clinical data of presently reported patients with 6p22.3-p24.1 deletions
(Continued)
Kyphosis + - - - -
Hand anomalies Cl, variable short
metacarpal bones
Cl Cl Cl -
Foot anomalies Pes planovalgus, Sy
2–4 toes, SG,
crooked 4th toes ul
3rd toes, short and
broad H, variable
short metatarsal
bones
Pes planovalgus, Sy
2–4 toes
Ul 5th toes, 2nd and
4th toes lying over
3rd toes
Sy 2–3 toes, SG,
broad H
-
Dental anomalies Pointed dens
caninus
- Irregularly placed
frontal teeth
- -
Legend: +, feature present; -, feature absent; ?, not cooperative for sufficient assessment, ASDs; autism spectrum disorders; Cl, clinodactyly 5th fingers; F, female; H,
halluxes; M, male; NE, not examined; Nl, normal; SG, sandal gap; Sy, syndactyly; Ul, underlying.
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were detected by aCGH analysis in the five patients
(Table 1 and Figure 2 and 3). Patients 4 and 5 carried
non-overlapping deletions that were both included in the
deletions of Patients 1–3. Patient 1 had a deletion involving
6p22.3-p24.1 of 4.8-4.9 Mb and Patient 2 had a 3.1 Mb
deletion overlapping the proximal 2.8 Mb of the deletion in
Patient 1. Array analysis in Patient 3 revealed a 2.3-2.6 Mb
deletion included in the region deleted in Patients 1 and 2,
and the common region deleted in these three patients
contained six genes: JARID2, DTNBP1, MYLIP, MIR4639,
GMPR and ATXN1. In Patient 4, we identified a 189–241
kb deletion, including part of the genes JARID2 and
DTNBP1, which was the region defining SRO I, deleted in
Patients 1–4. A 116–163 kb deletion was detected in
Patient 5 including the gene GMPR and part of the gene
ATXN1. This was the region defining SRO II, deleted in
Patients 1–3 and 5. The partial deletion of JARID2 and
DTNBP1 in Patient 4, and ATXN1 in Patient 5 removed
the 3’end of the genes, deleting exons 3–18 in JARID2,
exons 7–10 in DTNBP1 and exons 8–9 in ATXN1 and
the 3’ untranslated region (UTR) in all cases. Only copy
number variants (CNVs) covering minor parts of the
region deleted in our patients were recorded in the
Database of Genomic Variants (DGV, projects.tcag.ca/
variation, accessed in November 2012) (Figure 3). From
the aCGH result it was uncertain if the gene KDM1B was
deleted in Patient 2, as it was partly included in the region
between the last deleted and the first normal aCGH oligo
at the proximal border, and it was shown by qPCR not to
be deleted. No additional genes were located in the region
between the minimal and maximal sizes of the deletions,
and the breakpoints of the deletions given by the aCGH
results were therefore not investigated further. All five
chromosome 6 deletions were verified, by qPCR (Patients
1–4) or by performing a second aCGH with higher reso-
lution (Patient 5), and were found to be de novo by aCGH
analysis of the parental samples. In addition, the aCGH
analysis detected a 463 kb duplication of chromosome
4q23 in Patient 3 (chr4:100124832–100588141, bp) and a
94 kb deletion of chromosome 11p13 in Patient 5 (chr11:
Figure 2 Array-CGH results in Patients 1-5 (A-E) revealing deletions in chromosome 6p22.3-p24.1. The shaded area indicates the deleted
area with an average log2-ratio of -1, indicating loss of one copy of the genomic segment.
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32697424–32791452, bp). Two DECIPHER patients (iden-
tification # 250971 and # 256563) were reported with a
duplication that overlaps the duplicated region in Patient
3. However, both duplications were larger (both about
3.6 Mb), and one of the individuals also had two other
aberrations. Similarly, one DECIPHER patient (identifica-
tion # 253354) had a deletion covering the region deleted
in Patient 5, which also was larger (4.1 Mb). A minor
part of the duplication of chromosome 4q23, and most
of the deletion of chromosome 11p13 overlapped with
CNVs in DGV. These aberrations in Patient 3 and 5
were inherited from healthy parents and the gene con-
tent did not appear relevant for the clinical presentation
of the patients.
Expression of JARID2 and ATXN1 measured by RT-PCR
was analyzed in the four patients that carried a deletion in-
volving the gene(s) (Patients 1–4 and Patients 1–3 and 5,
respectively) and in eight healthy controls, using RNA
from leucocytes. The expression levels of JARID2 and
ATXN1 were normalized to the levels of the three
housekeeping genes, HPRT, PPIB and HMBS, which
showed the most homogenous expression in the five
patients among totally ten control genes analyzed.
JARID2 expression was significantly reduced in our
patients compared to controls (p ≤ 0.01) (Figure 4A).
ATXN1 expression in the patients was not significantly
different from controls (p ≤ 0.1), but a trend towards
reduced expression was observed (Patients 2 and 3 had
a reduced expression level) (Figure 4B).
Discussion
Although deletions in 6p22-p24 have been suggested to be
relatively rare, 19 patients have so far been studied
[1,2,4,9-15]. We detected five new patients with de novo
deletions in chromosome 6p22.3-p24.1 in a cohort of
about 3600 patients investigated in our diagnostic labora-
tory on the indication developmental delay, ASDs and/or
congenital abnormalities (Table 1 and Figure 2 and 3). The
molecular and clinical data of all 24 patients are summa-
rized in Table 2. Chromosome 6p22-p24 haploinsufficiency
results in a clinically heterogeneous neurodevelopmental
syndrome. However, most of the patients manifest develop-
mental delay and variable degree of cognitive impairment,
and various dysmorphic facial features. Neurological abnor-
malities, such as epileptic seizures, lack of coordination
and/or muscular hypotonia were recorded in 16 patients.
ASDs and/or behavioural abnormalities, including stereo-
typic behaviour, aggressiveness, attention deficits and motor
hyperactivity were described in 12 patients. Nine patients
had a structural heart defect, and eight patients had skeletal
anomalies. The different breakpoints and sizes (0.1-17 Mb)
of the deletions are likely to account for a large part of the
phenotypical variability.
Figure 3 Localization of the deletions in chromosome 6p22.3-p24.1 in our five patients (top) and the overlapping part of the deletions
in 17 out of 19 previously reported patients. SRO I in Patients 1-4 from the present report is 189 kb (red box), and SRO II in Patients 1-3 and 5
is 116 kb (green box). JARID2 and ATXN1 are deleted in 14 and 16 patients, respectively. Patient codes and deletion coordinates for previous
patients are according to [1], except M from [2]. CNVs recorded in the Database of Genomic Variants (projects.tcag.ca/variation) (below) are
covering only a minor part of the region deleted in the five patients. For the two genes located within the SRO I, a single CNV in JARID2 was
located in an intronic sequence, and two CNVs were reported in DTNBP1: one located in an intronic sequence and one copy number gain
including the 5’UTR and the first exon. For the two genes located within SRO II, no CNVs were reported in GMPR and one CNV, a gain in an
intronic sequence observed in three individuals, was recorded in ATXN1. Data were uploaded into UCSC Genome Browser (genome.ucsc.edu).
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We detected the two smallest deletions within 6p22-p24
reported so far, defining two SROs in our five patients: SRO
I in Patients 1–4 and SRO II in Patients 1–3 and 5, both
located in 6p22.3 (Figure 3). Manifestation of cognitive
impairment in both Patients 4 and 5, in spite of non-
overlapping deletions, suggests that two dosage sensitive
genes, within SRO I and II, independently contribute to
cognitive impairment when deleted. Each SRO contained
only two genes, allowing us to focus on candidate genes for
the features shared by the patients.
In spite of the heterogeneous phenotype associated with
6p22-p24 deletions, we recognized a similar phenotype in
our four patients with deletion of SRO I, consisting of gait
disturbance and recognizable facial dysmorphic features, in
addition to borderline IQ or intellectual disability. SRO I
was defined by the 189 kb deletion in Patient 4, and
included the genes DTNBP1 and JARID2.
DTNBP1, dystrobrevin binding protein 1, encodes for
dysbindin which is part of the Biogenesis of Lysosome-
related Organelles Complex-1 (BLOC-1) [16]. BLOC-1 reg-
ulates intracellular protein trafficking and is implicated in
the biogenesis of specialized organelles of the endoso-
mal–lysosomal system [17]. DTNBP1 genetic variants
have been linked to general cognitive ability [18-20].
Furthermore, SNPs in this gene have been extensively
associated with schizophrenia [21-23]. In vitro studies indi-
cated dysbindin as a binding partner of several proteins
with a suggested role in muscular physiology [24-26], and
increased dysbindin transcript and protein levels were mea-
sured in muscle biopsies from individuals and mice with
0
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JARID2
JARID2-1 JARID2-2 JARID2-3 JARID2-4 HPRT PPIB HMBS
ATXN1-1 ATXN1-2 ATXN1-3 HPRT PPIB HMBS
Figure 4 Expression levels of JARID2 (A) and ATXN1 (B) in leucocytes from our four patients with deletion of one or both of these
genes (Patients 1-4 and Patients 1-3 and 5, respectively), compared with eight healthy controls. JARID2 and ATXN1 levels were measured
using four and three primer pairs targeting the transcripts, respectively (JARID2-1, -2, -3 and -4, and ATXN1-1, -2 and -3). Primer sequences are
given in Additional file 1: Table S1). JARID2 expression level was significantly reduced in the patients compared to the controls (p ≤ 0.01), while
the ATXN1 expression level was not significantly altered (p ≤ 0.1). Ctrl, Control; Pt, Patient.
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Table 2 Summary of deletion data and clinical presentation of all published patients with 6p22-p24 deletions
Pt
(a)
Reference Gender Age
(b)
Chr6 coordinates (hg19) (c) Size
(Mb)
(d)
DD/
ID
Neurological
abnormalities
ASDs Behavioural
abnormalities
(e)
Structural
heart
defects
Skeletal
anomalies
Dental
anomalies
Hernia Dysmorphic
features
1 Present
report
F 15y 13071924-17918584 bp 4.8 + + - + N/A + + - +
2 Present
report
M 4y 15081747-18207178 bp 3.1 + + - + + N/A - - +
3 Present
report
F 6.5y 14545576-16846846 bp 2.3 + + + + - N/A + + +
4 Present
report
M 6.5y 15405377-15594945 bp 0.2 + (f) + - - N/A N/A - - +
5 Present
report
F 17y 16215803-16332297 bp 0.1 + (+) (g) - + N/A N/A - - -
1 [1] M 15y 13662096-19042218 bp 5.1 + + + + - + N/A N/A +
2 [1] M 4y 16572367-17543199 bp 1.0 + N/A (+)
(h)
+ N/A N/A N/A N/A -
3 [1] F 1m 9621501-24218259 bp 14.6 N/A N/A N/A N/A + N/A N/A N/A +
4 [1] M 17y 10269968-13915223 bp 3.6 + + - + - + N/A N/A +
5 [1] F 7y 16186391-21421705 bp 5.2 + + - N/A N/A N/A N/A N/A -
6 [1] M 3y 12058814-20896726 bp 8.8 + + - + + + + N/A +
A [14] M 3y (2.3-4.2) – (25.2-27.0) or
(13.4-15.2) – (30.4-32.1) Mb
N/A + + N/A N/A + + N/A + +
B [12] M 9m (7.1-13.4) – (15.2-25.2) Mb N/A N/A + N/A N/A + N/A N/A + +
C [9, Pt 1] M 15y 14.4 – 21.6 Mb N/A + + N/A (+) (i) N/A N/A + + +
D [9, Pt 2] F 13m 11.9 – 18.7 Mb N/A + + N/A N/A + N/A N/A N/A +
E [10, Pt 91–
145]
F 34m (13.0-14.0) – 21.7 Mb N/A + + N/A N/A N/A N/A N/A - +
F [10, Pt 95–
800]
M 20y 10.0 – 15.8 Mb N/A + + N/A + N/A + - +
G [10, Pt PF] M 4y 10.0 – 18.7 Mb N/A + N/A N/A N/A N/A - N/A + +
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Table 2 Summary of deletion data and clinical presentation of all published patients with 6p22-p24 deletions (Continued)
H [11] M 23m (4.2-6.1) – (10.4-11.9) Mb N/A N/A N/A N/A N/A + + N/A N/A +
I [13, Pt
AU010604]
M N/A 13889301-15153952 bp 1.3 N/A N/A + N/A N/A N/A N/A N/A N/A
J [15] F 16y 14446670-27741682 bp 13.3 + + N/A + + + + N/A +
K [4] F 4y 16132021-23152021 bp 7.0 + N/A - - + N/A N/A - +
L [1] N/A N/A 18829825-23576125 bp 4.7 + + + N/A N/A N/A N/A N/A +
M [2] F 11y 17281809-24786325 bp 7.5 + N/A N/A N/A N/A N/A N/A N/A +
Total 20 16 (17) 4 (5) 10 (11) 9 8 5 5 20
Legend: +, feature present; ASDs, autism spectrum disorders; chr, chromosome; DD, developmental delay; F, female; ID, intellectual disability; M, male; m, month-old; N/A, information not available; Pt, patient; y, year-
old; (a) codes for previous patients are according to [1], except from M [2]; (b) age at last examination; (c) deleted region for previous Patients 1–6 and A-L from [1], and in M deduced from the deleted genes noted by
the authors [2]; (d) minimum size; (e) includes a wide spectrum of behavioural abnormalities, possibly also undiagnosed ASD; (f) borderline intellectual functioning (IQ =74); (g) possibly present; (h) suspected to have
ASDs, but not formally tested; (i) poor concentration.
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Duchenne Muscular Dystrophy (DMD; MIM 310200)
[27,28]. However, muscle pathology was not reported in
mutant Dtnbp1 mice [16], and not detected in BLOC-
1-deficient mice [29]. One patient with homozygous
nonsense mutation in DTNBP1 causing the recessive
pigmentation and bleeding disorder Hermansky Pudlak
Syndrome 7 (HPS7; MIM 614076) [16] was reported.
Manifestations of cognitive impairment, muscle weakness,
impaired balance and coordination, gait disturbance or
dysmorphic features were not reported in this patient.
Thus a link between DTNBP1 haploinsufficiency and the
features seen in our patients is unlikely.
The second gene included in SRO I, JARID2 (jumonji,
AT rich interactive domain 2), encodes a transcriptional
repressor protein. Studies of the murine orthologous Jarid2
have shown that the encoded protein acts via methylation
modifications that regulate developmental processes
(reviewed by Takeuchi [30]), as well as organ homeostasis
[31]. In particular Jarid2 has an important function in
Prc2 and Notch1 pathways. Polycomb group (PcG) of pro-
teins, consisting of Prc1 and Prc2, has central roles in epi-
genetic regulation of development, differentiation and
maintenance of cell fate in embryonic stem cells [32,33].
Jarid2 recruits Prc2 to target genes and contributes to the
establishment of high levels of lysine 27 methylation of
Histone 3 (H3K27), leading to gene repression [34,35].
Notch signaling decides cell fates during development,
and is critical for a variety of developmental programs,
including in the central nervous system (reviewed by
Yoon and Gaiano [36]). Four paralogues genes encoding
the receptor proteins Notch 1–4 have been identified in
vertebrates. Jarid2 has been shown to bind to the
Notch1 locus, promoting di- and tri-methylation of lysine
9 on Histone 3 (H3K9me2 and H3K9me3), and repressing
the transcription of Notch1 (Notch, Drosophila, homolog
of, 1) [37]. Jarid2 knockout embryos have decreased levels
of H3K9me2 and H3K9me3 and exhibit persistent high
expression of Notch1. Although this mechanism was
detected in the developing heart of the mice, Jarid2
might exert similar functions on Notch1 in other organ
systems [37].
According to NCBI gene, Human Genome Variation
Society (HGVS) and the 1000 Genome Project databases,
no disease causing mutations have previously been
described in JARID2 in humans. However, haploinsuffi-
ciency of several histone methyltransferase genes is known
to result in syndromic intellectual disability exemplified by:
MLL2 (myeloid/lymphoid or mixed-lineage leukemia 2)
in Kabuki syndrome (MIM 147920) and EHMT1
(Euchromatic Histone Methyltransferase 1) in Kleefstra
syndrome (MIM 610253). Loss of function mutations in
the lysine-specific demethylase JARID1C, another gene of
the JARID family, also causes syndromic intellectual dis-
ability (MIM 300534). In addition, two studies have shown
association between JARID2 and ASDs, when using the
data from the Autism Genetic Resource Exchange (AGRE)
[38,39]. Based on these observations, we suggest that
JARID2 is likely to be the critical gene within SRO I, and
the main gene causing the neurodevelopmental syndrome
in Patients 1–4. In support of this, we performed an RNA
expression study showing that the JARID2 expression level
was significantly decreased in these four patients
(Figure 4A).
We found that our four patients with JARID2 deletion
had a similar facial appearance (Figure 1 and Table 1), in
whom the most characteristic findings were prominent
supraorbital ridges, deep set eyes, dark infraorbital circles
and midface hypoplasia. These features were not consis-
tently reported in the 10 previously described patients with
JARID2 deletion (Patients 1, 3, 6 from [1], A, C-G and J,
Table 2 and Figure 3), but when we carefully inspected the
photos available for seven of these individuals, a similar
facial pattern could be confirmed. Although mild, the men-
tioned dysmorphic facial features were a consistent finding
in these patients. Therefore, JARID2 haploinsufficiency may
result in a clinically recognizable neurodevelopmental
syndrome.
In our four patients with JARID2 haploinsufficiency, we
also observed impairment of balance and coordination, and
gait disturbance, which were more pronounced in
Patients 1 and 4. The peculiar gait in Patients 1 and 4
(see Additional file 2: Video Patient 1 and Additional
file 6: Video Patient 4) was interpreted as a sign of dys-
praxia, suggesting a higher brain function deficit. Cerebral
MRI examinations in these patients did not reveal patho-
logical changes affecting the cerebellum. Patients 2 and 3
were not cooperative for sufficient assessment of putative
dyspraxia. Impaired balance and coordination and/or gait
disturbance were noted in four out of the 10 previously
reported patients with JARID2 deletion (Patients 6, A, C
and J, Table 2), but a common etiology could not be identi-
fied. Developmental dyspraxia was described in Patient 6
[1], while clear indications of cerebellar ataxia were not
reported in any of them. Muscular hypotonia was recorded
in additional four patients without any specific reference to
gait (Patients 1 from [1] and D-F).
SRO II, deleted in Patients 1–3 and 5, was defined by the
116 kb deletion in Patient 5 who presented with mild intel-
lectual disability and behavioural abnormalities. This region
included the genes GMPRI and ATXN1.
Guanosine monophosphate reductase (GMPR) catalyzes
the irreversible deamination of guanosine monophosphate
(GMP) to inosine monophosphate (IMP), and plays a
role in maintaining the intracellular balance of A and G
nucleotides [40]. According to NCBI gene, HGVS and
the 1000 Genome Project databases, no disease causing
mutations in this gene have previously been linked to
neurodevelopmental syndromes.
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ATXN1 (ataxin-1), is well known for causing the
dominantly inherited spinocerebellar ataxia type 1
(SCA1; OMIM 164400), mainly due to a gain of function
mechanism upon expansion of a (CAG)n repeat. Atxn1
knockout mice show deficits in spatial and learning mem-
ory, but not ataxic signs or neurodegeneration [41]. How-
ever, ablation of wild type Atxn1 in the knock-in SCA1
mouse model (Atxn1154Q/+), resulted in a more severe
SCA1 phenotype [42]. In addition, Atxn1 −/− mice shared
transcriptional alterations with Atxn1154Q/+, possibly
contributing to pathogenesis in SCA1 [35,43].
Similarly to JARID2, ATXN1 also encodes for a transcrip-
tional repressor protein, which acts on different pathways
including Silencing Mediator of Retinoid and Tyroid
Receptor (SMART), Histone Deacetylase (HDAC) 3 and 4,
Capicua and LANP. In Drosophila and mouse cell lines,
ATXN1 has been shown to act on the Notch pathway
through interaction with the transcriptional corepressor
CBF1 [44]. In addition, an association between SNPs in this
gene and intelligence was reported in patients ascertained
for ADHD [45].
Celestino–Soper et al. suggested that haploinsufficiency
of ATXN1 is associated with developmental delay and
ASDs [1]. The statement relied on the evidence that 10 out
of 13 previous patients with a deletion including this gene
(Patients 1–3, 5 and 6 from [1], A, C-E, G, J-K and possibly
B, which is uncertain due to low resolution mapping of the
breakpoints) showed speech delay, ASDs, ADHD or other
abnormal behaviour. Among these 10 patients, however,
only one had a diagnosis of ASDs (Patient 1 from [1]), while
another one possibly had ASDs but was not formally tested
(Patient 2 from [1]), and a third one was defined as having
a sensory processing brain disorder (Patient 6 from [1]).
Furthermore, two patients (I and L), both had intact
ATXN1 and a diagnosis of ASDs, clearly indicating that
ASDs in patients with 6p22-p24 deletion is not exclusively
caused by ATXN1 haploinsufficiency. Our four patients
with ATXN1 deletion exhibit behavioural abnormalities,
but only Patient 3 fulfils the diagnostic criteria of ASDs.
ATXN1 haploinsufficiency therefore seems to result in
intellectual disability with high risk of behavioural abnor-
malities, but not necessarily ASDs. We did not detect a
significantly reduced ATXN1 expression level in our four
patients with a deletion of this gene, even though a trend of
reduced levels was found (Figure 4B). The variation in
expression levels between individuals, both for controls and
patients, was seen for ATXN1. Because of this inter model
individual variation, additional patients with an ATXN1
deletion are needed to asses if this deletion leads to a
reduced ATXN1 expression. The RNA from the patients
was isolated from leucocytes, and it cannot be excluded
that a significantly reduced level would have been detected
using RNA from specific brain regions.
We find it noteworthy that Patient 1, as the only one of
our five patients, had variable length of the metacarpal and
metatarsal bones of hands and feet. Although without
X-ray images, a similar appearance of the foot, with broad
and short halluxes and long 2nd toes was described in
Patient 1 from [1]. Haploinsufficiency of a gene located
within these two patients' shared deletion overlap may
cause disruption of skeletal growth.
In conclusion, chromosome 6p22-p24 haploinsufficiency
results in a clinically heterogeneous neurodevelopmental
syndrome, probably reflecting the different breakpoints and
sizes and the lack of overlap between all deletions. The
histone modifiers, ATXN1 and JARID2, exert their effect on
several target genes and possibly explain part of the pheno-
type. Interestingly, both ATXN1 and JARID2 act on the
Notch pathway, an evolutionary conserved signalling
pathway whose dysregulation can have a broad impact on
developmental processes, including development of the
central nervous system, which could be relevant in our
patients.
We remark that JARID2 deletion-patients in addition to
cognitive impairment presented with gait disturbance and a
characteristic facial appearance that may represent a
clinically recognizable developmental syndrome, and that
patients with an ATXN1 deletion seemed to be character-
ized by intellectual disability and behavioural abnormalities.
Simultaneous deletion of the two genes likely exacerbated
the degree of intellectual disability in three of our patients.
Previously both JARID2 and ATXN1 were linked to ASDs,
but in our patients we detected a wider spectrum of
behaviour abnormalities, rather than a well-defined diagno-
sis of ASDs, which only one of the patients had. Because
JARID2 haploinsufficiency appears to result in a clinically
recognizable developmental syndrome, we suggest that this
gene should be sequenced in future patients with a similar
phenotype when a gene deletion is not present.
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Additional file 1: Table S1. RT-PCR primer sequences.
Additional file 2: Video Patient 1 demonstrating impaired balance
and coordination when asked to stand and jump on one leg and to
walk in a straight line.
Additional file 3: Figure S1. (A) X-ray images of hands of Patient 1
showing shortening of the 1st and 3rd-5th metacarpal bones left hand,
and the 1st and 5th metacarpal bones right hand. (B) X-ray images of
feet showing bilateral short 1st metatarsal bones.
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Additional file 4: Video Patient 2 demonstrating mild gait
disturbance with broad-based legs.
Additional file 5: Video Patient 3 demonstrating stereotypic
behavioural abnormalities with an intense compulsion for walking.
Note slightly broad-based legs.
Additional file 6: Video Patient 4 demonstrating impaired balance
and coordination when asked to stand and jump on one leg and to
walk in a straight line.
Competing interest
The authors declare no conflicts of interests.
Authors’ contributions
Clinical evaluation of patients has been performed by ASP, AB, BT, MF and
PS. OKR, AH, AS, TB and DM performed cytogenetic and molecular studies.
TB drafted the manuscript. EF supervised and coordinated the study and
critically revised the manuscript. DM, JRH, BT and PS critically revised the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We are grateful to the patients and their families for participating in this
study. We thank collaborating physicians: Petra Aden, Karin Benan, Susanne
Henning, Cecilie Fremstad Rustad and Rebekka Johnsen Wangensteen, and
psychologist Marianne Winge Hesla. We thank the Section for Genetic
Diagnostic Laboratories at the Department of Medical Genetics, Oslo
University Hospital, for performing diagnostic tests. This work was supported
by a grant from the Southeastern Regional Health Authorities (project no
2011071). EF was supported by “Sigurd K. Thoresens Foundation” and
“Legatet til Henrik Homans Minde”, and DM was supported by “Anders
Jahres fond til vitenskapens fremme”.
Author details
1Department of Medical Genetics, University of Oslo, P.O. Box 1036, Blindern,
Oslo N-0315, Norway. 2Women and Children's Division, Department of
Clinical Neurosciences for Children, Oslo University Hospital, Ullevål, Norway.
3Faculty of Medicine, University of Oslo, Oslo, Norway.
Received: 30 August 2012 Accepted: 3 January 2013
Published: 7 January 2013
References
1. Celestino-Soper PB, Skinner C, Schroer R, Eng P, Shenai J, Nowaczyk MM,
Terespolsky D, Cushing D, Patel GS, Immken L, et al: Deletions in
chromosome 6p22.3-p24.3, Including ATXN1, are associated with
developmental delay and autism spectrum disorders. Mol Cytogenet
2012, 5:17.
2. Izu A, Yanagida H, Sugimoto K, Fujita S, Sakata N, Wada N, Okada M,
Takemura T: Pathogenesis of focal segmental glomerular sclerosis in a
girl with the partial deletion of chromosome 6p. Tohoku J Exp Med 2011,
223:187–192.
3. Colmant C, Brisset S, Tachdjian G, Gautier V, Ftouki M, Laroudie M, Druart L,
Frydman R, Picone O: Interstitial deletion 6p22.3-p24.3 characterized by
CGH array in a foetus with multiple malformations. Prenat Diagn 2009,
29:908–910.
4. Bremer A, Schoumans J, Nordenskjold M, Anderlid BM, Giacobini M: An
interstitial deletion of 7.1Mb in chromosome band 6p22.3 associated
with developmental delay and dysmorphic features including heart
defects, short neck, and eye abnormalities. Eur J Med Genet 2009,
52:358–362.
5. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for
biologist programmers. Methods Mol Biol 2000, 132:365–386.
6. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(−delta delta C(T)) method.
Methods 2001, 25:402–408.
7. Vandesompele J, De PK, Pattyn F, Poppe B, Van RN, De PA, Speleman F:
Accurate normalization of real-time quantitative RT-PCR data by
geometric averaging of multiple internal control genes. Genome Biol
2002, 3:RESEARCH0034.
8. Juliusson PB, Roelants M, Eide GE, Moster D, Juul A, Hauspie R, Waaler PE,
Bjerknes R: [Growth references for norwegian children]. Tidsskr Nor
Laegeforen 2009, 129:281–286.
9. Davies AF, Olavesen MG, Stephens RJ, Davidson R, Delneste D, Van RN,
Vamos E, Flinter F, Abusaad I, Ragoussis J: A detailed investigation of two
cases exhibiting characteristics of the 6p deletion syndrome. Hum Genet
1996, 98:454–459.
10. Davies AF, Mirza G, Sekhon G, Turnpenny P, Leroy F, Speleman F, Law C,
Van RN, Vamos E, Flinter F, et al: Delineation of two distinct 6p deletion
syndromes. Hum Genet 1999, 104:64–72.
11. Davies AF, Mirza G, Flinter F, Ragoussis J: An interstitial deletion of
6p24-p25 proximal to the FKHL7 locus and including AP-2alpha that
affects anterior eye chamber development. J Med Genet 1999, 36:708–710.
12. Moriarty AP, Kerrmuir MG: Sclerocornea and interstitial deletion of the
short Arm of chromosome-6-(46Xy Del[6] [P22 P24]). J Pediatr Ophthalmol
Strabismus 1992, 29:177–179.
13. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, Yamrom B,
Yoon S, Krasnitz A, Kendall J, et al: Strong association of de novo copy
number mutations with autism. Science 2007, 316:445–449.
14. van Swaay E, Beverstock GC, van de Kamp JJ: A patient with an interstitial
deletion of the short arm of chromosome 6. Clin Genet 1988, 33:95–101.
15. Zirn B, Hempel M, Hahn A, Neubauer B, Wagenstaller J, Rivera-Brugues N,
Strom TM, Kohler A: Polyneuropathy, scoliosis, tall stature, and
oligodontia represent novel features of the interstitial 6p deletion
phenotype. Am J Med Genet A 2008, 146A:2960–2965.
16. Li W, Zhang Q, Oiso N, Novak EK, Gautam R, O'Brien EP, Tinsley CL, Blake DJ,
Spritz RA, Copeland NG, et al: Hermansky-Pudlak syndrome type 7 (HPS-7)
results from mutant dysbindin, a member of the biogenesis of
lysosome-related organelles complex 1 (BLOC-1). Nat Genet 2003,
35:84–89.
17. Falcon-Perez JM, Starcevic M, Gautam R, Dell'Angelica EC: BLOC-1, a novel
complex containing the pallidin and muted proteins involved in the
biogenesis of melanosomes and platelet-dense granules. J Biol Chem
2002, 277:28191–28199.
18. Burdick KE, Lencz T, Funke B, Finn CT, Szeszko PR, Kane JM, Kucherlapati R,
Malhotra AK: Genetic variation in DTNBP1 influences general cognitive
ability. Hum Mol Genet 2006, 15:1563–1568.
19. Fallgatter AJ, Herrmann MJ, Hohoff C, Ehlis AC, Jarczok TA, Freitag CM,
Deckert J: DTNBP1 (dysbindin) gene variants modulate prefrontal brain
function in healthy individuals. Neuropsychopharmacology 2006,
31:2002–2010.
20. Zhang JP, Burdick KE, Lencz T, Malhotra AK: Meta-analysis of genetic
variation in DTNBP1 and general cognitive ability. Biol Psychiatry 2010,
68:1126–1133.
21. Morris DW, Murphy K, Kenny N, Purcell SM, McGhee KA, Schwaiger S,
Nangle JM, Donohoe G, Clarke S, Scully P, et al: Dysbindin (DTNBP1) and
the biogenesis of lysosome-related organelles complex 1 (BLOC-1): main
and epistatic gene effects are potential contributors to schizophrenia
susceptibility. Biol Psychiatry 2008, 63:24–31.
22. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M,
Albus M, Lerer B, Rietschel M, Trixler M, Maier W, et al: Support for
association of schizophrenia with genetic variation in the 6p22.3 gene,
dysbindin, in sib-pair families with linkage and in an additional sample
of triad families. Am J Hum Genet 2003, 72:185–190.
23. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C,
Wormley B, Sadek H, Kadambi B, et al: Genetic variation in the 6p22.3
gene DTNBP1, the human ortholog of the mouse dysbindin gene, is
associated with schizophrenia. Am J Hum Genet 2002, 71:337–348.
24. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ: Dysbindin, a
novel coiled-coil-containing protein that interacts with the dystrobrevins
in muscle and brain. J Biol Chem 2001, 276:24232–24241.
25. Benson MA, Tinsley CL, Blake DJ: Myospryn is a novel binding partner for
dysbindin in muscle. J Biol Chem 2004, 279:10450–10458.
26. Locke M, Tinsley CL, Benson MA, Blake DJ: TRIM32 is an E3 ubiquitin ligase
for dysbindin. Hum Mol Genet 2009, 18:2344–2358.
27. Sillitoe RV, Benson MA, Blake DJ, Hawkes R: Abnormal dysbindin
expression in cerebellar mossy fiber synapses in the mdx mouse model
of Duchenne muscular dystrophy. J Neurosci 2003, 23:6576–6585.
28. Wakayama Y, Matsuzaki Y, Yamashita S, Inoue M, Jimi T, Hara H, Unaki A,
Iijima S, Masaki H: Dysbindin, syncoilin, and beta-synemin mRNA levels in
dystrophic muscles. Int J Neurosci 2010, 120:144–149.
Barøy et al. Orphanet Journal of Rare Diseases 2013, 8:3 Page 13 of 14
http://www.ojrd.com/content/8/1/3
29. Nazarian R, Starcevic M, Spencer MJ, Dell'Angelica EC: Reinvestigation of
the dysbindin subunit of BLOC-1 (biogenesis of lysosome-related
organelles complex-1) as a dystrobrevin-binding protein. Biochem J 2006,
395:587–598.
30. Takeuchi T, Watanabe Y, Takano-Shimizu T, Kondo S: Roles of jumonji and
jumonji family genes in chromatin regulation and development. Dev Dyn
2006, 235:2449–2459.
31. Mejetta S, Morey L, Pascual G, Kuebler B, Mysliwiec MR, Lee Y, Shiekhattar R,
Di Croce L, Benitah SA: Jarid2 regulates mouse epidermal stem cell
activation and differentiation. EMBO J 2011, 30:3635–3646.
32. Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A, Wysocka J: Jarid2/
Jumonji coordinates control of PRC2 enzymatic activity and target gene
occupancy in pluripotent cells. Cell 2009, 139:1290–1302.
33. Shen X, Kim W, Fujiwara Y, Simon MD, Liu Y, Mysliwiec MR, Yuan GC, Lee Y,
Orkin SH: Jumonji modulates polycomb activity and self-renewal versus
differentiation of stem cells. Cell 2009, 139:1303–1314.
34. Pasini D, Cloos PAC, Walfridsson J, Olsson L, Bukowski JP, Johansen JV,
Bak M, Tommerup N, Rappsilber J, Helin K: JARID2 regulates binding of the
Polycomb repressive complex 2 to target genes in ES cells. Nature 2010,
464:306–U193.
35. Zhang Z, Jones A, Sun CW, Li C, Chang CW, Joo HY, Dai QA, Mysliwiec MR,
Wu LC, Guo YH, et al: PRC2 Complexes with JARID2, MTF2, and
esPRC2p48 in ES cells to modulate ES cell pluripotency and somatic cell
reprograming. Stem Cells 2011, 29:229–240.
36. Yoon K, Gaiano N: Notch signaling in the mammalian central nervous
system: insights from mouse mutants. Nat Neurosci 2005, 8:709–715.
37. Mysliwiec MR, Carlson CD, Tietjen J, Hung H, Ansari AZ, Lee Y: Jarid2
(Jumonji, AT rich interactive domain 2) regulates NOTCH1 expression via
histone modification in the developing heart. J Biol Chem 2012,
287:1235–1241.
38. Bureau A, Croteau J, Tayeb A, Merette C, Labbe A: Latent class model with
familial dependence to address heterogeneity in complex diseases:
adapting the approach to family-based association studies. Genet
Epidemiol 2011, 35:182–189.
39. Ramos PS, Sajuthi S, Langefeld CD, Walker SJ: Immune function genes
CD99L2, JARID2 and TPO show association with autism spectrum
disorder. Mol Autism 2012, 3:4.
40. Andrews SC, Guest JR: Nucleotide sequence of the gene encoding the
GMP reductase of escherichia coli K12. Biochem J 1988, 255:35–43.
41. Matilla A, Roberson ED, Banfi S, Morales J, Armstrong DL, Burright EN, Orr
HT, Sweatt JD, Zoghbi HY, Matzuk MM: Mice lacking ataxin-1 display
learning deficits and decreased hippocampal paired-pulse facilitation.
J Neurosci 1998, 18:5508–5516.
42. Lim J, Crespo-Barreto J, Jafar-Nejad P, Bowman AB, Richman R, Hill DE, Orr
HT, Zoghbi HY: Opposing effects of polyglutamine expansion on native
protein complexes contribute to SCA1. Nature 2008, 452:713–7U1.
43. Crespo-Barreto J, Fryer JD, Shaw CA, Orr HT, Zoghbi HY: Partial loss of
ataxin-1 function contributes to transcriptional dysregulation in
spinocerebellar ataxia type 1 pathogenesis. PLoS Genet 2010,
6:e1001021–e1001037.
44. Tong X, Gui H, Jin F, Heck BW, Lin P, Ma J, Fondell JD, Tsai CC: Ataxin-1 and
brother of ataxin-1 are components of the notch signalling pathway.
EMBO Rep 2011, 12:428–435.
45. Rizzi TS, Arias-Vasquez A, Rommelse N, Kuntsi J, Anney R, Asherson P,
Buitelaar J, Banaschewski T, Ebstein R, Ruano D, et al: The ATXN1 and
TRIM31 genes are related to intelligence in an ADHD background:
evidence from a large collaborative study totaling 4,963 subjects.
Am J Med Genet B Neuropsychiatr Genet 2011, 156:145–157.
doi:10.1186/1750-1172-8-3
Cite this article as: Barøy et al.: Haploinsufficiency of two histone
modifier genes on 6p22.3, ATXN1 and JARID2, is associated with
intellectual disability. Orphanet Journal of Rare Diseases 2013 8:3.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Barøy et al. Orphanet Journal of Rare Diseases 2013, 8:3 Page 14 of 14
http://www.ojrd.com/content/8/1/3
